Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-02
2010-10-05
Bausch, Sarae (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023500, C536S024310, C436S063000, C436S064000
Reexamination Certificate
active
07807364
ABSTRACT:
A method for determining whether a patient in need thereof will respond to anti-VEGF antibody based chemotherapy by screening a suitable cell or tissue sample isolated from the patient for at least one genomic polymorphism or genotype selected from (i) IL-8(−251); (ii) VEGF(936); or (iii) AM (3′ CA repeats), wherein the patient is suitably treated if the corresponding genotype is (i) (T/T) for IL-8(−251); (ii) (T/T or C/T) for VEGF(936); or (iii) at least one AM allele having 14 or more 3′ CA repeats.
REFERENCES:
patent: 6716581 (2004-04-01), Lenz et al.
patent: 2004/0011625 (2004-02-01), Lenz
patent: 2004/0067519 (2004-04-01), Lenz et al.
patent: 2006/0094012 (2006-05-01), Lenz et al.
patent: 2006/0115827 (2006-06-01), Lenz
patent: 2007/0218487 (2007-09-01), Lenz
patent: 2007/0244083 (2007-10-01), Lenz
patent: 2008/0286789 (2008-11-01), Lenz et al.
patent: 2009/0181016 (2009-07-01), Lenz
patent: WO 2004/011625 (2004-02-01), None
Erichsen et al. (Br J. Cancer, 2004, vol. 90, pp. 747-751).
Hirshhorn et al. (Genetics in Medicine, 2002, 4(2): 45-61).
Balasubramanian et al. (2002) “Role of genetic polymorphisms in tumour angiogenesis”Br. J. Cancer87(10):1057-1065.
Ban et al. (1996) “Transfection of glutathione 5-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide”Cancer Res.56(15):3577-3582.
Bello et al. (2006) “Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3”Proc ASCO24:4045.
Du Manoir et al. (2006) “Strategies for delaying or treating in vivo acquired resistance to Trastuzumab in human breast cancer xenografts,”Clin. Cancer Res.12:904-916.
Eberhart et al. (1994) “Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas”Gastroenterology107(4):1183-1188.
Edelman (1988) “Morphoregulatory molecules”Biochem.27(10):3533-3543.
Evans and Relling (1999) “Pharmacogenomics: translating functional genomics into rational therapeutics”Science286(5439):487-491.
Folkman (2002) “Role of angiogenesis in tumor growth and metastasis”Semin. Oncol.29(6 Suppl 16):15-18.
Gorski et al. (1999) “Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation”Cancer Res.59(14):3374-3378.
Goto et al. (1999) “Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells”Free Rad. Res.31(6):549-558.
Iqbal et al. (2003) “Targeted therapy and pharmacogenomic programs,”Cancer97:2076-2082.
Kastan et al. (1991) “Participation of p53 protein in the cellular response to DNA damage”Cancer Res.51(23 Pt 1):6304-6311.
Lenz (2004) “The use and development of germline polymorphisms in clinical oncology”J. Clin. Oncol.22(13):2519-2521.
Lenz (2006) “Pharmacogenomics and colorectal cancer”Adv. Exp. Med. Biol.587:211-231.
Levine (1992) “The p53 tumor-suppressor gene”N. Engl. J. Med.326(20):1350-1352.
Levine et al. (2004) “Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies”Proc ASCO23:3008.
Mallik et al. (2004) “Polymorphisms in IL-8 and the GSTP1 are associated with survival of metastatic colorectal cancer patients treated with CPT-11”Proc ASCO23:3606.
Mauceri et al. (1996) “Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature”Cancer Res.56(19):4311-4314.
Mauceri et al. (1998) “Combined effects of angiostatin and ionizing radiation in antitumour therapy”Nature394(6690):287-291.
Maurer et al. (1998) “Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer”Int. J. Cancer79(1):76-81.
Miller et al. (2005) “Randomized phase III trial of capecitabine compared with Bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer,”Journal of Clinical Oncology23:792-799.
Nunez et al. (1996) “Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells”Radiother. Onc.39(2):155-165.
Park and Lenz (2006) “Determinants of chemosensitivity in gastric cancer”Curr. Opin. Pharma.6(4):337-344.
Ruoslahti (1988) “Fibronectin and its receptors”Ann. Rev. Biochem.57:375-413.
Stoehlmacher et al. (2002) “Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer”J. Nat. Cancer Inst.94(12):936-942.
Wachsberger et al. (2003) “Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction”Clin. Cancer Res.9(6):1957-1971.
Yan and Beckman (2005) “Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development”Biotechniqes39(4):565-568.
Yanagisawa et al. (1998) “Increased expression of human DNA repair genes, XRCC1, XRCC3 and RAD51, in radioresistant human KB carcinoma cell line N10”Oral Oncol. 34(6):524-528.
Yang et al. (2004) “Gene expressions of VEGF and Survivin as molecular markers of lymph node involvement in patients with locally advanced rectal cancer”Proc ASCO23:9526.
Yuan et al. (2000) “Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer”Am. J. Respir. Crit. Care Med.162(5):1957-163.
Yun et al. (2003) “Association of genetic polymorphisms of IL-8 and its receptor CXCR1 and survival of patients with metastatic colorectal cancer treated with 5FU/oxaliplatin”Proc ASCO22:847.
Zhang et al. (2003) “Interleukin-8 (IL-8) promoter region gene polymorphism predicts pelvic recurrence after chemo-radiation in patients with rectal cancer”Int. J. Radiat. Oncol. Riol. Phys.57(2):S382.
Zhang et al. (2006) “Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab”Pharma. Genomics16(7):475-483.
Azuma et al. (2007) “Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)”J. Clin. Oncol., ASCO Ann. Mtg. Proc. I, vol. 25(18S)(Jun. 20 Suppl):4113.
Chang et al. (2007) “Gene expression levels of HER2 and IL-8 and polymorphisms in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial,”J. Clin. Oncol., ASCO Ann. Mtg. Proc. I, vol. 25(18S)(Jun. 20 Suppl):4647.
Fox, et al. (1998) “Angiogenesis in Normal Tissue Adjacent to Colon Cancer,”Journal of Surgical Oncology69(4):230-234.
Ishimitsu , et al. (2003) “Variations of human adrenomedullin gene and its relation to cardiovascular diseases,”Hypertension Research26(1):129-134.
Jin, et al. (2005) “Vascular endothelial growth factor polymorphisms in relations to breast cancer development and prognosis,”Clinical Cancer Research11(10)3647-3653.
Kuniyasu, et al. (2000) “Induction of Angiogenesis by Hyperplastic Colonic Mucosa Adjacent to Colon Cancer,”American Journal of Pathology157(5):1523-35.
Ladner et al. (2007) “Polymorphisms in estrogen receptor beta, interleukin-8, and interleukin-8 receptor associated with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-flourouracil/oxaliplatin,”J. Clin. Oncol., ASCO An
Bausch Sarae
Foley & Lardner LLP
Konski Antoinette F.
University of Southern California
LandOfFree
Angiogenesis pathway gene polymorphisms for therapy selection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Angiogenesis pathway gene polymorphisms for therapy selection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiogenesis pathway gene polymorphisms for therapy selection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201715